Janux Therapeutics Inc

Janux Therapeutics is a clinical-stage biopharmaceutical company whose research and development pipeline relies on animal testing. The company’s lead programs in oncology and immunology are in preclinical and early clinical phases, a stage of drug development where animal models are standard for evaluating efficacy and safety. While specific details of Janux’s internal protocols are not publicly documented, the company operates within an industry sector where animal testing is a foundational and required component of the regulatory approval pathway for new therapeutics.

An audit of U.S. laboratories in 2025 documented hundreds of animal welfare violations, indicating systemic issues with animal suffering in research settings. As a company developing novel biologic and small-molecule drugs, Janux’s operations fall under this broader regulatory and institutional framework for animal research. The company has not published a formal animal welfare policy or alternative testing commitment that would distinguish its practices from the industry norm.